The biotech industry is off to a strong start this year, with Ever Supreme reporting a January revenue of NT$59.51 million, marking an 11.23% year-over-year increase and a record high for the same period. General Manager Huang Wen Liang stated that the company’s cell therapy contract development and manufacturing (CDMO) business has secured visibility through the fourth quarter, with an expanding network of partner hospitals and growing cell therapy projects. He remains optimistic about operations in 2025, expecting continued record-breaking performance.
Ever Fortune AI, having achieved a record-high revenue of NT$345 million last year, plans to distribute a cash dividend of NT$1 per share as a return to shareholders. With the increasing number of medical device approvals both domestically and internationally and the steady launch of new products, the company remains optimistic about its 2025 outlook. Market estimates suggest that its annual revenue growth rate will start at 40% and above.
Ever Supreme also reached a record-high revenue of NT$939 million last year, reflecting a 23.6% annual growth. Boosted by gains from the sale of investments such as Omnigen, the company projects a full-year pre-tax earnings per share (EPS) of up to NT$6. Plans are in place to fully distribute stock and cash dividends to reward shareholder support.
Huang Wen Liang highlighted that Ever Supreme continues to expand its drug pipeline, advancing stem cell research alongside targeted exosome therapies to revolutionize myocardial infarction treatment. The company’s allogeneic umbilical cord mesenchymal stem cell therapy (UMSC01) employs a dual-route injection approach for treating damaged heart tissue. Currently in Phase IIa clinical trials, UMSC01 marks the first stem cell-based myocardial infarction therapy in Taiwan to reach this stage. Ten patients have already undergone treatment, and cardiopulmonary exercise testing (CPET) results indicate that patients in the treatment group exhibited greater cardiopulmonary function improvement compared to the control group, with no severe adverse effects observed. These findings demonstrate both safety and potential efficacy.
Ever Fortune AI stated that its planned NT$1 per share cash dividend is subject to approval by the board of directors and shareholders. The company has already secured 43 medical device approvals worldwide, including 12 from the U.S. FDA, 16 from Taiwan’s TFDA, 5 from Thailand, 5 from Malaysia, 4 from Vietnam, and 1 from Singapore, further strengthening its market position.
Having distributed cash dividends of NT$2 and NT$1 per share in 2022 and 2023, respectively, Ever Fortune AI is set to become the first medical AI company in Taiwan to maintain dividend payouts for three consecutive years.
Resource: 長聖 1月營收創同期新高
